Article in Nanomedicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Sivakumar S MoniDepartment of Pharmaceutics, College of Parmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0002-4860-0166
Siddig Ibrahim AbdelwahabHealth Research Centre, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0002-6145-4466
Syam MohanHealth Research Centre, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0003-2077-1278
Yassine RiadiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia.ORCID 0000-0002-5128-0765
Mohamed Eltaib ElmobarkDepartment of Pharmaceutics, College of Parmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0003-0546-6697
Razan Willie AreshyiPharm.D students, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0009-0007-9059-5923
Hissah Ali SofyaniPharm.D students, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0009-0009-5851-1069
Fatma Ahmad HalawiPharm.D students, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0009-0008-8983-6168
Manar Qasem HakamiPharm.D students, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0009-0008-4117-4310
Ieman A AljahdaliDepartment of Clinical Laboratory Sciences, Taif University, Taif, 11099, Saudi Arabia.
Bassem OraibiHealth Research Centre, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0001-9207-9411
Abdullah FarasaniHealth Research Centre, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0001-6942-5136
Ogail Yousif DawodDepartment of Physical Therapy, College of Nursing and Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0002-4439-0173
Hassan Ahmad AlfaifiMinistry of Health Pharmaceutical Care Administration (Jeddah Second Health Cluster), Jeddah, 21589, Saudi Arabia.
Amal Hamdan AlzahraniCollege of Pharmacy, Department of Pharmacology & Toxicology, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Ahmed Ali JerahDepartment of Medical Laboratory Technology, College of Nursing & Health Sciences, Jazan University, Jazan, 45142, Saudi Arabia.
Funding
Deanship of Graduate Studies and Scientific Research, Jazan University, Saudi Arabia RG24-M014
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsCetuximabDoxorubicinNanoparticlesSodium SeleniteCell SurvivalDrug CarriersDrug Delivery SystemsDrug LiberationFemaleHumansMCF-7 CellsParticle SizeCetuximabDoxorubicinDrug CarriersSodium Selenitebreast cancercetuximbdoxorubicinnanoparticlessodium selenitetargeted delivery system
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Cetuximab-conjugated sodium selenite nanoparticles for doxorubicin targeted delivery against MCF-7 breast cancer cells. · full record | Socratic